FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. HC Wainwright upgraded FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Price Performance

Shares of NASDAQ FGEN opened at $0.48 on Tuesday. The company has a 50-day simple moving average of $0.36 and a 200-day simple moving average of $0.55. The company has a market cap of $48.37 million, a PE ratio of -0.39 and a beta of 0.82. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the previous year, the firm posted ($0.52) earnings per share. On average, analysts anticipate that FibroGen will post -0.86 EPS for the current year.

Institutional Trading of FibroGen

Several institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd raised its position in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA acquired a new stake in FibroGen during the second quarter worth about $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of FibroGen in the 2nd quarter worth about $130,000. Sei Investments Co. lifted its stake in shares of FibroGen by 38.4% in the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 41,442 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of FibroGen during the 2nd quarter worth about $145,000. 72.71% of the stock is owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.